Oxford Vaccine Jabs
- All
- News
- Videos
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
AstraZeneca UK Vaccine Trial On Children Paused As Clot Link Probed
A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.
-
"Proud To Take The Jab": What Natasha Poonawalla Said On Serum Institute's Covishield
Natasha Poonawalla, Serum Institute of India's Executive Director, was today vaccinated against COVID-19. She received the first shot of Covishield which is manufactured by her company and developed by AstraZeneca and Oxford University.
-
3-Month Gap Between Oxford Vaccine Jabs Gives Better Efficacy: Study
A three-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.
-
Britain's Spies Defending COVID-19 Vaccine Work, MI5 Chief Says
British spies are trying to defend COVID-19 vaccine work against hostile powers that seek to either steal or sabotage research data in the race for the global prize of a jab that could provide immunity, the head of MI5 said on Wednesday.
-
Oxford University Begins Human Trial Of Coronavirus Vaccine
Oxford University is launching a human trial of a potential coronavirus vaccine, with the daunting aim of making a successful jab available to the public later this year.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
AstraZeneca UK Vaccine Trial On Children Paused As Clot Link Probed
A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.
-
"Proud To Take The Jab": What Natasha Poonawalla Said On Serum Institute's Covishield
Natasha Poonawalla, Serum Institute of India's Executive Director, was today vaccinated against COVID-19. She received the first shot of Covishield which is manufactured by her company and developed by AstraZeneca and Oxford University.
-
3-Month Gap Between Oxford Vaccine Jabs Gives Better Efficacy: Study
A three-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.
-
Britain's Spies Defending COVID-19 Vaccine Work, MI5 Chief Says
British spies are trying to defend COVID-19 vaccine work against hostile powers that seek to either steal or sabotage research data in the race for the global prize of a jab that could provide immunity, the head of MI5 said on Wednesday.
-
Oxford University Begins Human Trial Of Coronavirus Vaccine
Oxford University is launching a human trial of a potential coronavirus vaccine, with the daunting aim of making a successful jab available to the public later this year.
